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Abstract
Background: Diabetes mellitus is a major global issue 
and high quality testing is essential for the diagnosis and 
treatment of the disease. The IFCC Committee for the Edu-
cation in the Utility of Biomarkers in Diabetes (C-EUBD) 
plays a global role in improving knowledge and under-
standing around diabetes testing. This paper describes a 
multi-stakeholder approach, to improving diagnostic and 
therapeutic testing for diabetes, using a multicentre study 
in China as an example of the global impact of the group.
Methods: Educational workshops were developed to 
support the scientific aims of the study in which 30 centres 
around China received identical, fresh frozen whole blood 
samples with values assigned using IFCC secondary ref-
erence methods and undertook precision (EP-5) and true-
ness studies. Performance was assessed using sigma 
metrics.
Results: A successful multi-stakeholder group was devel-
oped and sustained throughout the study through several 
educational workshops, which enabled the formation of 
a long-term collaboration with key opinion leaders and 
policy makers in China. All 30 centres showed good per-
formance with within and between laboratory coefficient 
of variations (CVs) below 3% in SI units at both low and 
high haemoglobin A1c (HbA1c) levels. All individual labora-
tories met the criteria of a sigma of two or more at a total 
allowable error (TAE) of 5 mmol/mol (0.46% NGSP).
Conclusions: The study led to a successful multi-partner 
approach to improving diabetes testing in China. All cen-
tres involved in the study meeting the published IFCC 
quality criteria, paving the way for future clinical trials 
and an expanded role for HbA1c testing across the country.
Keywords: China; HbA1c; IFCC; multicentre study; sigma 
metrics; standardisation.
Introduction
Diabetes mellitus is a global health issue which results 
in significant morbidity, mortality and economic burden, 
with an estimated one in 11 adults having the disease [1]. 
Essential to tackling this global epidemic is early identifi-
cation and effective management of the disease. Crucial 
to these objectives is high quality, standardised, reliable 
haemoglobin A1c (HbA1c) testing, without which it would 
be impossible to set accurate diagnostic thresholds or 
beneficial treatment targets.
The mission statement for the IFCC Education and 
Management Division (EMD) highlights their ambition 
to ‘provide the healthcare community with education 
relevant to Clinical Chemistry and Laboratory Medicine, 
directed at scientific, management and clinical issues’ [2]. 
The division is home to a number of committees, each with 
a specific clinical or analytical area of focus, together they 
work collectively towards supporting the education and 
knowledge exchange of laboratory personnel, clinicians, 
patients and policy makers in order to have significant 
impact on the way in which diagnostic testing is perceived 
and used to improve health.
The Committee for Education in the Use of Biomarkers 
in Diabetes (C-EUBD) sits within the EMD and is focussed 
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on education strategies for global implementation of HbA1c 
standardisation and other biomarkers associated with dia-
betes care which is essential to ensure the ongoing clinical 
utility of these markers [3]. Implementation of standardisa-
tion of a diagnostic test requires key components such as a 
reference measurement procedure (RMP), reference mate-
rials and a reference laboratory network. Alongside these, 
appropriate clinical reference intervals/decision limits are 
needed, with defined quality targets for the analyte. Inter-
nal quality control (IQC) and external quality assessment 
(EQA) are needed to monitor that the quality of the results 
produced, meets the quality targets that have been set [4]. 
The C-EUBD and predecessor committees have developed 
and implemented each of these key components to satisfy 
the needs of standardisation of HbA1c [5–7]. However, adop-
tion, knowledge and understanding of the process remains 
a global issue with a number of barriers to truly successful 
standardisation remaining.
In order to contextualise the barriers to effective 
implementation of personalised medicine Horgan et  al. 
undertook a systematic review of policy and literature to 
define key areas of focus [8]. The key themes identified 
were scientific, operational, economic and legislative bar-
riers, which are also applicable to the implementation of 
the standardisation of diagnostic tests.
In scientific terms, the analytical standardisation 
and the role of HbA1c in diagnostic testing and monitor-
ing of people with diabetes is well established. However, 
specific treatment targets and the most appropriate diag-
nostic threshold are topics that are still widely debated, 
with not all countries adopting the test for diagnosis or 
using the 48  mmol/mol (6.5%) threshold advised [9]. 
Analytically, high quality equipment is available for the 
measurement of HbA1c however, the extent to which this is 
available or utilised on a global level is unclear, with some 
countries using re-badged or locally manufactured instru-
ments in which the link to the IFCC RMP has not been 
demonstrated. The IFCC C-EUBD continues to work with 
expanding numbers of manufacturers to ensure calibra-
tion to the RMP through the network of reference labora-
tories [10]. The committee is also engaged in studies which 
will address clinical issues, reviewing the evidence for the 
diagnostic thresholds and working towards defining per-
sonalised targets for HbA1c monitoring.
In operational terms, information delivery, education 
and training, empowerment of patients and health profes-
sionals and introduction of regulations are all barriers to 
effective implementation of standardised HbA1c testing. The 
provision of clinical decision support systems, education 
around interpretation of results and their communication 
to patients, and improving health literacy to adjust public 
expectations and knowledge around diabetes testing are 
all needed to overcome these barriers. The IFCC Task Force 
on Implementation of HbA1c Standardisation (TF-HbA1c) 
started to address these issues with lecture series and review 
articles to support understanding and knowledge around 
the analytical process of standardisation. The current 
C-EUBD is taking this further with workshops funded by UK 
research councils and industry partners aimed at improv-
ing knowledge and understanding in health professionals 
in areas such as result interpretation, analytical perfor-
mance of both main laboratory and POC instruments, the 
value of EQA programmes and expanded roles for HbA1c in 
other disease areas [11, 12].
Economic barriers to the effective use of HbA1c testing 
are a particular hindrance in low and lower middle 
income countries where the test cost is simply too high 
to be affordable with many insurance companies not cov-
ering the cost of testing, keeping demand low. The low 
demand, in turn, maintains a high test cost, resulting in 
a self-perpetuating cycle that will only be broken if either 
test demand increases or test cost falls or both [13]. The 
C-EUBD, is working with industry partners to facilitate 
pilot studies to improve access to testing in low resource 
setting such as sub-Saharan Africa and parts of the Asia-
Pacific region, in turn this will generate wider implemen-
tation of testing in these areas.
Regulatory and guideline barriers are multi-faceted 
issues. Different countries or regions have different regula-
tory guidance, for example, in Europe legislation dictates 
that manufacturers must demonstrate that their instru-
ments are traceable to higher-order references such as the 
IFCC-RMP for HbA1c [14]. However, whilst the consensus 
statement of key clinical and scientific bodies associated 
with diabetes care advises the same practice, it is not man-
datory on a global level. Amongst the scientific and clini-
cal communities there is a high level of engagement with 
the concept of implementation of HbA1c standardisation, 
however in order to effect a change it is the government 
and non-government organisations (NGOs) who commis-
sion healthcare provision that need to be engaged. The 
C-EUBD is building collaborative links with such organi-
sations to ensure a multi-stakeholder approach is taken 
to addressing the barriers to implementation of HbA1c 
standardisation.
For the implementation of standardisation to be a true 
success all stakeholders need to work together to ensure 
that patient care remains consistent and optimal. One 
such example of the way in which the C-EUBD aims to 
engage all stakeholders to tackle barriers in each of the 
main themes above, is through a collaborative multi-cen-
tre trial in China, which we describe in this paper.
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A barrier to the introduction of HbA1c for diagnosis in 
China is a lack of evidence to demonstrate that the quality 
targets for HbA1c can be met across the country, at the indi-
vidual laboratory level or across a network of laboratories 
which may form an EQA scheme. The aims of this study 
were to assess the analytical performance of 30 clini-
cal centres across China using the international quality 
standards [6] and to assess the logistical issues associ-
ated with creating a quality network. Key stakeholders 
include, industry partners (Trinity Biotech, Bray, Ireland), 
the Chinese Diabetes Society (CDS), the IFCC C-EUBD and 
leading clinical centres across the country.
Materials and methods
Participating centres
This large study was conducted in 30 laboratories across China. 
 Centres were chosen to gain a representative geographical and pop-
ulation based sample. Participating centres are listed in Table 1, in 
alphabetical order. In order to maintain confidentiality for each centre 
this does not represent the centre numbers used in the data analysis.
Knowledge exchange workshops
Workshops were developed and held in Beijing and Shanghai with 
clinical and laboratory staff from each of the participating centres as 
well as national key opinion leaders able to meet, sponsored as part 
of the study.
Instrument
Each laboratory utilised a Premier Hb9210 automated benchtop HbA1c 
analyser (Trinity Biotech, Bray, Ireland) which uses boronate affinity 
high performance liquid chromatography (HPLC) for measurement of 
HbA1c. The performance of the analyser in a multicentre setting has 
previously been shown to be adequate [15]. The Hb9210 system was 
calibrated using a two-point calibration as per the manufacturer’s 
instructions. Calibrator values were assigned by the manufacturer 
using secondary calibration material supplied by the IFCC Standard-
isation Network as recommended in the consensus statement [16].
Sample preparation and storage
Each laboratory was supplied with a set of 50 (25 duplicates) HbA1c 
samples for the trueness study and 20 samples for the imprecision 
study. The set of 50 samples was generated by mixing pooled sam-
ples, collected from multiple donors; a high pool (78  mmol/mol 
[9.3% NGSP]) and low pool (31.2 mmol/mol [5% NGSP]) were mixed 
in varying increments to achieve a range of HbA1c values. Donor 
samples (700 mL) were collected into di-potassium EDTA containing 
tubes. Before mixing the volume of the plasma in the sample with 
the lowest haemoglobin concentration was adjusted to ensure that 
the haemoglobin concentrations of the high and low donations were 
equivalent. Aliquots of 0.25 mL of each of the 50 samples were indi-
vidually labelled in cryo-vials with red caps to help differentiate from 
the imprecision samples, and packaged into labelled boxes before 
being shipped to participating laboratories. Samples were prepared 
on the day of collection and prior to shipment samples were stored at 
−80 °C and shipped to participating centres on dry ice.
Samples for the imprecision studies were prepared as above 
with low sample values of (37.6 mmol/mol, [5.6% NGSP] yellow caps) 
and high of (59.0 mmol/mol, [7.5% NGSP] blue caps). Samples were 
shipped to participating laboratories on dry ice.
All samples were tested and found negative for Hepatitis B Sur-
face Antigen (HBsAg), antibody to hepatitis C (HCV), antibody to HIV 
and HIV antigen.
Target value assignment
The target values of all of the samples were assigned in duplicate 
with each of six IFCC calibrated routine methods Tosoh G8; ARKRAY/
Menarini HA 8180V, Sebia Capillarys 2 Flex Piercing, Roche Tina 
Quant Gen 3 on Cobas c513 and Trinity Biotech Premier Hb9210 (two 
instruments) at the European Reference Laboratory, Queen Beatrix 
Hospital, Winterswijk and Isala, Zwolle, The Netherlands.
Imprecision
Imprecision was assessed using a Clinical and Laboratory Standards 
Institute (CLSI) EP-5 [17] based protocol with low and high samples 
measured twice a day, in duplicate, for 20 working days.
Trueness
Each laboratory received 50  samples (25 duplicates) which were ana-
lysed in a single batch on two separate days [18]. The laboratories were 
blinded to the values of the samples prior to analysis. Bias was assessed 
by plotting the measured vs. expected results and a simple linear regres-
sion line calculated. The bias at a target value of 50 mmol/mol (6.7% 
NGSP) was calculated and further used in the quality target analysis.
Quality targets
The assessment of performance for each laboratory, both individually 
and as a group, was performed using the IFCC TF-HbA1c, guidance 
on the use of sigma metrics for quality targets [6]. In the laboratory 
sigma-metrics is a quality management strategy that provides a uni-
versal benchmark for process performances. Analytical characteris-
tics (bias and imprecision) in the form of total allowable error (TAE) 
are placed within a framework of clinical requirements. The TAE was 
set at 5 mmol/mol (0.46% NGSP) with a minimum sigma value of 2 to 
pass the evaluation criteria.
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Statistical analysis
Statistical analyses were performed using Microsoft® Excel 2010 
(Microsoft Corporation) and EP-Evaluator Release 11 (Data Innova-
tions) [19].
Laboratory protocol
Laboratories were instructed to undertake a structured familiarisation 
study of the analyser in order to ensure that they were efficient and 
competent with the use of the instrument before commencement of the 
main study protocol. Essentially the familiarisation protocol assessed 
imprecision and bias in a 7-day protocol. The results of the familiarisa-
tion study are not included in the main evaluated data. Once the famil-
iarisation study was complete the participants requested the delivery 
of the main study samples for analysis. A detailed handbook for both 
the familiarisation and main studies was compiled and translated into 
Chinese to ensure the protocol was consistently performed.
Ethics statement
Ethical approval for the study was granted by the University of East 
Anglia Faculty of Medicine and Health Sciences Research Ethics 
Committee (ref: 20152016-21).
Results
Stakeholder engagement
Engagement from participating centres, IFCC  committee 
members, key opinion leaders from China and key 
policy makers such as representatives of the CDS was 
achieved.
Table 1: List of participating centres’ names and location.
Hospital name   Hospital location
Chinese Center for Disease Control and Prevention ( )   Beijing
Chinese PLA General Hospital ( )   Beijing
Guangdong Province Traditional Chinese Medical Hospital ( )   Guangzhou
Guizhou Provincial People’s Hospital ( )   Guiyang
Haikou People’s Hospital ( )   Haikou
Jiangxi Provincial People’s Hospital ( )   Nanchang
Jilin Central Hospital ( )   Jilin
Jinyang Hospital of Guiyang ( )   Guiyang
Liuzhou Municipal Liutie Central Hospital ( )   Liuzhou
Peking Union Medical College Hospital ( )   Beijing
Peking University First Hospital ( )   Beijing
Peking University People’s Hospital ( )   Beijing
Shanghai Changzheng Hospital ( )   Shanghai
Shanghai Putuo People’s Hospital ( )   Shanghai
Shanghai Yangpu District Central Hospital ( )   Shanghai
The 6th People’s Hospital Affiliated to Shanghai Jiaotong University, Shanghai Diabetes Institute 
( )
  Shanghai
The First Affiliated Hospital of Chongqing Medical University ( )   Chongqing
The First Affiliated Hospital of Zhengzhou University ( )   Zhengzhou
The First Hospital of China Medical University ( )   Shenyang
The General Hospital of Shenyang Military ( )   Shenyang
The Second Hospital of Dalian Medical University ( )   Dalian
The Third People’s Hospital of Shenzhen ( )   Shenzen
Tianjin Hospital ( )   Tianjin
Tong Ren Hospital Shanghai Jiao Tong University School of Medicine ( )  Shanghai
Tongji Hospital, Tongji Medical College of Hust ( )   Wuhan
Wenzhou Central Hospital ( )   Wenzhou
Women’s Hospital School of Medicine Zhejiang University ( )   Hangzhou
Wuzhou Red Cross Hospital ( )   Wuzhou
Zhejiang Provincial Hospital of Traditional Chinese Medicine ( )   Hangzhou
Zhongshan City People’s Hospital ( )   Zhongshan
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Imprecision
The results of the EP-5 analysis for each individual labora-
tory are detailed in Table 2. Coefficient of variations (CV) 
values for the low samples ranged from 1.1 to 2.6% and CV 
values for the high samples ranged from 0.9 to 2.7%, well 
within the 3% target often cited for CV calculated using 
mmol/mol units [20, 21]. At the low level the mean HbA1c for 
all laboratories was 37.59 mmol/mol (5.6% NGSP) at a target 
value of 37.6 mmol/mol (5.6% NGSP). At the high level the 
mean for all laboratories was 57.91 mmol/mol (7.4% NGSP) 
at a target value of 59.0  mmol/mol (7.5% NGSP), thus an 
acceptable difference of 1.09 mmol/mol.
All of the mean values were analysed for outliers using 
the Q-Test. With a critical value for Q of 0.23 the values for 
the low and high CVs of centre 10 and the high CV for centre 
23  were excluded from subsequent analysis, despite CV 
values within a range that would normally be acceptable.
At the low level the mean within lab CV was 1.86% 
and the between lab CV was calculated as the mean of 
the SDs divided by the target value for the samples  ×  100 
(0.97/37.6 × 100%) giving a value of 2.6%.
At the high level the mean within lab CV was 1.49% 
and the between lab CV was 1.20/57.8 × 100% = 2.1%. It is 
widely recognised that the ratio of the between/within lab 
CV is commonly approximately 1.5. Is this study the ratio is 
2.6/1.86 = 1.4 and at the high level 2.1/1.49 = 1.4. The higher 
the ratio the less control a manufacturer has on batches 
of reagents/calibrators, however, this ratio is considered 
acceptable.
Trueness
The results of the comparison study (against IFCC targeted 
values) are shown in Table 3. The individual laboratory 
Table 2: EP-5 imprecision data for each participating centre.
Lab number Ep 5 low CV, % Mean, mmol/mol Ep 5 high CV, % Mean, mmol/mol
1 1.9 37.6 1.3 58.1
2 1.4 38.7 1.6 58.2
3 2 36.8 2 57.8
4 1.6 37.1 1.8 59.5
5 2.5 37.8 2.7 59.3
6 2.4 36.7 1.9 57.8
7 2.5 37.8 1.2 57
8 2 36.5 1.4 57.6
9 2 36.4 1.5 56
10 2 34.5 2 53.9
11 1.4 38.5 0.9 58.4
12 2.1 37.2 1.7 56.8
13 1.4 37.7 1.4 56.6
14 1.4 36.5 1.2 55.3
15 1.4 39.5 1.1 59
16 1.8 38.3 1 58.4
17 2.5 37.5 1.7 56.8
18 2.6 36.4 1.3 59.5
19 1.1 37.8 0.9 57.7
20 1.9 39.2 1.6 60.2
21 1.4 38.3 0.9 58.6
22 2.1 36.1 1.5 56.6
23 1.4 38.5 2.2 51.4
24 1.6 35.6 1.4 56.6
25 1.8 38.1 1.4 58
26 1.9 38.2 1.3 58.1
27 1.9 38.5 1.3 58.3
28 1.5 38.4 0.9 58.9
29 2.3 36.4 1.6 56.5
30 1.9 37.9 2.0 59.8
Mean 1.86 37.59 1.49 57.91
Standard deviation 0.97 1.20
Results highlighted in italics were deemed to be outliers and not included in the mean and SD calculations.
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CVs were calculated from the 25 duplicate samples, with 
the regression lines and bias at 50 mmol/mol (6.7%) cal-
culated for each centre. The performance of all labora-
tories as a group was also assessed for imprecision and 
trueness. Supplementary Table 1 details the target values 
and bias for all laboratories for the calculation of group 
performance data.
Sigma metrics
When the IFCC model for quality targets was applied at a 
level of 2 σ each of the participating centres was deemed 
to have achieved a satisfactory performance level. Figure 
1 demonstrates the within laboratory performance, with 
each point representing an individual centre. It can be 
seen that there is a wide performance range with some 
laboratories performing significantly better than the TAE 
of 5 mmol/mol at the 2 σ level. Additional coloured bands 
of bronze, silver and gold, represent reducing TAE levels 
of 3, 2 and 1 mmol/mol TAE, respectively.
The performance of all participating centres as a group 
is shown in Figure 2. The bias of all laboratories was calcu-
lated from the target value minus the mean of all laborato-
ries (see Supplementary Table 1). The between laboratory 
CV was calculated and plotted against the between labo-
ratory bias. The samples were divided into low, medium 
and high values as shown in Figure 2. Overall 48 out of 
the 50 samples met or exceeded 2 σ and were deemed to 
Table 3: Bias calculation for each centre at a target value of 
50 mmol/mol (6.7% NGSP).
Centre 
code
  CV from 25 
duplicates, %
  r2  Y = ax + b   Bias at 
50 mmol/mol
01   0.9  0.9982  Y = 1.013x + 1.04   +1.7
02   1.0  0.9975  Y = 1.007x + 1.20   +1.6
03   1.5  0.9964  Y = 1.034x − 0.86   +0.8
04   1.4  0.9966  Y = 1.040x + 0.67   +1.3
05   1.1  0.9972  Y = 1.092x − 1.39   +3.2
06   1.8  0.9956  Y = 1.027x + 0.37   +1.7
07   1.1  0.9978  Y = 0.978x + 2.14   +1.0
08   1.8  0.9936  Y = 1.018x − 0.03   +0.9
09   0.8  0.9986  Y = 0.973x + 0.90   −0.4
10   2.7  0.9918  Y = 0.968x + 0.90   −0.7
11   1.1  0.9958  Y = 0.987x + 2.57   +1.9
12   1.3  0.9975  Y = 0.991x + 1.25   +0.8
13   2.1  0.9948  Y = 0.932x + 1.96   −1.5
14   1.5  0.9963  Y = 0.992x − 0.33   −0.7
15   1.3  0.9968  Y = 0.964x + 1.89   +0.1
16   1.2  0.9947  Y = 1.005x + 1.06   +1.3
17   1.1  0.9981  Y = 0.911x + 2.93   −1.5
18   2.9  0.9903  Y = 0.996x − 1.21   −1.4
19   1.4  0.9939  Y = 0.986x + 1.58   +0.9
20   1.6  0.9940  Y = 0.987x + 2.58   +1.9
21   1.0  0.9980  Y = 0.990x + 1.28   +0.8
22   1.0  0.9976  Y = 0.985x + 0.39   −0.4
23   1.7  0.9954  Y = 0.960x + 0.04   −2.0
24   1.5  0.9964  Y = 0.969x + 0.07   −1.5
25   3.4  0.9831  Y = 0.997x + 1.23   +1.1
26   3.0  0.9891  Y = 1.019x + 0.65   +1.6
27   1.6  0.9937  Y = 0.980x + 1.70   +0.7
28   1.5  0.9934  Y = 0.986x + 1.47   +0.8
29   2.1  0.9948  Y = 0.932x + 1.96   −1.5
30   1.5  0.9949  Y = 0.9979 + 0.71   +0.6
All labs  0.8  0.9984  Y = 0.9902x + 0.97   0.5
Figure 1: Individual laboratory performance using sigma metrics 
quality targets.
Figure 2: Performance of all participating centres as a group, with 
samples divided into low (green dot), medium (black dot) and high 
(red dot) values.
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have passed the quality standards. Statistically it can be 
expected that one out of 20 results will not be within the 
target limits (thus two out of 50 is acceptable).
There was little difference in performance between 
samples with low and high HbA1c concentrations. The 
between laboratory CV is slightly lower in the samples 
with the high HbA1c levels. Bias is also slightly lower in 
samples with the high HbA1c however, differences were 
small. It can be concluded that the project succeeded in 
achieving standardisation across 30 laboratories in China 
using a single HbA1c analyser.
Discussion
Using a multi-stakeholder approach the aim of this study 
was to assess the barriers to generating a network of 
laboratories, across a large country, where each centre 
is capable of producing HbA1c values that are aligned to 
international reference measurement values and the ana-
lytical performance at each laboratory meets published 
international quality criteria. This is important as it is a 
major requirement to enable the roll out of HbA1c for diag-
nosis of type 2 diabetes mellitus (T2DM) in accordance with 
World Health Organization (WHO) guidance. The aim was 
also to generate a network of laboratories with between 
laboratory analytical agreement which is good enough 
to support multicentre trials in the future, providing an 
essential service for population based studies. Finally, the 
study was successful in forging strong partnerships and 
collaborations with key stakeholders involved in the com-
missioning and delivery of diabetes care and is the first 
multi-centre study of its kind both in terms of scale and 
scope.
The study utilised fresh frozen whole blood samples 
with target values traceable to the IFCC RMP and each of 
the 30 centres received identical samples and  instruments, 
which minimised uncertainty in the estimation of trueness. 
Each individual laboratory demonstrated  performance at 
or above the 2 σ level with a TAE of 5 mmol/mol. In order 
to stimulate further improvement in quality a reduced TAE 
may be used, with 14 laboratories performing at a TAE of 
3  mmol/mol or less and six at 2  mmol/mol TAE or less. 
Each individual laboratory has demonstrated the ability 
to produce accurate and precise results and the enhanced 
performance shown by some demonstrates that there is 
already a stimulus towards ever improving quality. The 
use of a single method type may be seen as a limitation of 
this study as it is preferable to assess quality using a range 
of methods which represent the ‘real-world’ situation. 
However, the decision was made to utilise a single method 
type in this study to reduce the potential for uncertainty, 
as it was the process as a whole that was being assessed.
When the results are viewed as a group rather than 
individual centres then the key questions to be addressed 
are; can HbA1c be measured at any laboratory and gener-
ate the correct result? And does this performance apply 
at all HbA1c levels? Even when outliers were considered, 
all centres passed the IFCC criteria therefore it is possible 
to conclude that HbA1c can be measured correctly at any/
all of the centres. Secondly, the performance of the group 
at normal, medium and high levels showed that 48 out of 
the 50 samples also passed the IFCC criteria with results 
tightly clustered, demonstrating good performance at all 
HbA1c levels.
The WHO statement on the use of HbA1c for diagnosis 
states that a cut off of 6.5% (48 mmol/mol) should be used 
but only if the method used is aligned to the international 
reference values and that stringent quality assurance tests 
are in place [9].
The second requirement of the WHO statement is 
that stringent quality assurance tests are in place, to 
demonstrate the accuracy of the measurement system 
being used. Where national EQA schemes or proficiency 
testing (PT) schemes are available and are fit for purpose, 
engagement with these may enable the use of HbA1c for 
diagnosis.
Overall, this unique, large-scale study has shown that it 
is possible to generate a network of laboratories across China 
that provides a standardised measurement of HbA1c values 
which meet the IFCC criteria for analytical performance and 
are aligned to the international reference values [6].
This in turn fulfils the first element of the WHO 
 criteria for the use of HbA1c for the diagnosis of T2DM. 
This network could also be used to form the basis of a 
national quality scheme thus meeting the second element 
of the WHO criteria in addition to supporting high quality 
results for the monitoring of patients already diagnosed.
Importantly this joint project between CDS, clinical 
centres, the IFCC and industry has demonstrated that it 
is possible to engage multiple stakeholders in a common 
purpose to improve diabetes testing across China. This 
engagement has led to the formation of a new partnership 
between the IFCC C-EUBD and the CDS who together will 
devise guidance on diabetes testing and support change 
across China in future years. This has been an immensely 
successful project demonstrating the value and impact of 
the IFCC EMD and its committees.
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